Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

September 10, 2019 10 September, 2019

Sernova Completes Oversubscribed Private Placement of $4,684,564

Source: Sernova Corp

September 10, 2019 9:00 a.m. EDT

LONDON, ONTARIO –September 10, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which Sernova issued a total of 23,422,822 Units in three closings (August 16, 2019, August 30, 2019 and September 9, 2019).

Net proceeds from the private placement will be used to support funding of Sernova's clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial, “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch(TM) for Clinical Islet Transplantation” and to advance internal preclinical development programs and corporate/academic collaborations utilizing the Company’s platform technologies to treat diabetes, hemophilia and other serious disease conditions, as well as for investor relations and general corporate purposes.

Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one common share purchase warrant (“Warrant”). Each Warrant will be exercisable into one share at a price of $0.30 per share for a period of 36 months.

The private placement has received approval of the TSX Venture Exchange. Pursuant to applicable Canadian securities laws, the securities issued under the Private Placement are subject to a four-month hold period from the time of closing of the Private Placement. The hold periods for this Private Placement expire on December 17, 2019, December 31, 2019, and January 10, 2020.

The Company compensated finders by way of cash fees of $78,225 and 391,125 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants.

About Sernova’s US Clinical Study

The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

Fax: (519) 858-5099

Toll-Free: (877)-299-4603

dominic.gray@sernova.com

www.sernova.com

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.